Wed Jan 22 2020
ViroGates announces that it has completed the development and regulatory approval (CE-IVD) of its suPARnostic® TurbiLatex product for the ADVIA® Chemistry XPT System from Siemens Healthineers.
This is ViroGates’ first validation of the suPARnostic® TurbiLatex product for a Siemens Healthineers instrument. Siemens Healthineers is one of the leading players in the global in-vitro diagnostics market.
ViroGates’ suPARnostic® TurbiLatex product can now be implemented in clinical routine use at hospitals using the ADVIA XPT systems.
The ADVIA XPT is one of the automated clinical chemistry analysers placed in laboratories at the hospitals. The system can run up to 2,400 samples per hour and work as a fully automated system, requiring no manual handling from the blood sampling until results are processed.
The approval of suPARnostic® TurbiLatex for the ADVIA XPT platform complements the previous approvals for the Roche Diagnostics cobas systems.
The suPARnostic® TurbiLatex product is based on a technology called turbidimetry, that measures the loss of intensity of transmitted light due to the scattering effect of particles suspended in the blood sample.
suPARnostic® TurbiLatex is a particle-enhanced turbidimetric assay. The principle of measuring blood samples by using turbidimetry is important in relation to immunoassays. It is the basis of almost all central laboratory clinical chemistry instrument platforms in hospitals.